PMID- 31290564
OWN - NLM
STAT- MEDLINE
DCOM- 20191113
LR  - 20200108
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 46
IP  - 9
DP  - 2019 Sep
TI  - Infliximab reduces activated myeloid dendritic cells, different macrophage 
      subsets and CXCR3-positive cells in granuloma annulare.
PG  - 808-811
LID - 10.1111/1346-8138.14981 [doi]
AB  - Disseminated granuloma annulare (GA) is a rare granulomatous dermatitis of 
      unknown etiology. Treatment is often challenging and lack of a uniformly 
      effective treatment, adds to the disease morbidity. Tumor necrosis factor (TNF)-alpha 
      is an important cytokine in granuloma formation and previous reports have shown 
      improvement of disseminated GA with anti-TNF-alpha therapy. Nevertheless, the 
      underlying mechanism of actions of TNF-alpha inhibitors in GA remains unclear. Our 
      aim was to evaluate alterations in the inflammatory infiltrate in a patient who 
      experienced complete clearance of GA after treatment with infliximab. A skin 
      biopsy was obtained before and 24 weeks after treatment with infliximab 5 mg/kg 
      at weeks 0, 2, 6, 14 and 24. Immunohistochemical stains were performed in pre- 
      and post-treatment biopsy specimens using CD1a, CD4, CD8, CD11c, CD32, CD68, 
      CD69, CD163, CD183 and human leukocyte antigen (HLA)-DR to characterize 
      alterations of the infiltrates. Parallel with clinical improvement, we observed a 
      marked decrease in myeloid (CD11c) dendritic cells, different macrophage subsets 
      (CD68, CD32, CD163) and T cells. In addition, a marked reduction of activation 
      markers (HLA-DR, CD69) and CD183(+) (CXCR3) cells was observed in post-treatment 
      biopsy specimens. In conclusion, the clinical improvement of disseminated GA by 
      infliximab is paralleled by inhibition of activated myeloid dendritic cells, 
      different macrophage subsets and type 1 T cells.
CI  - (c) 2019 Japanese Dermatological Association.
FAU - Burgler, Christina
AU  - Burgler C
AUID- ORCID: 0000-0003-1412-1869
AD  - Department of Dermatology and Venereology, Inselspital, Bern University Hospital, 
      University of Bern, Bern, Switzerland.
FAU - Vinay, Keshavamurthy
AU  - Vinay K
AD  - Department of Dermatology, Venereology and Leprology, Postgraduate Institute of 
      Medical Education and Research, Chandigarh, India.
FAU - Hafliger, Stefanie
AU  - Hafliger S
AD  - Department of Dermatology and Venereology, Inselspital, Bern University Hospital, 
      University of Bern, Bern, Switzerland.
FAU - Klotgen, Hans-Wilhelm
AU  - Klotgen HW
AD  - Department of Dermatology and Venereology, Inselspital, Bern University Hospital, 
      University of Bern, Bern, Switzerland.
FAU - Yawalkar, Nikhil
AU  - Yawalkar N
AD  - Department of Dermatology and Venereology, Inselspital, Bern University Hospital, 
      University of Bern, Bern, Switzerland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20190710
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (CXCR3 protein, human)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Receptors, CXCR3)
RN  - 0 (TNF protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Aged
MH  - Biopsy
MH  - Dendritic Cells/*drug effects/immunology/metabolism
MH  - Dermatologic Agents/*pharmacology/therapeutic use
MH  - Granuloma Annulare/*drug therapy/immunology/pathology
MH  - Humans
MH  - Infliximab/*pharmacology/therapeutic use
MH  - Macrophages/*drug effects/immunology/metabolism
MH  - Male
MH  - Receptors, CXCR3/immunology/metabolism
MH  - Skin/cytology/drug effects/pathology
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors/immunology
OTO - NOTNLM
OT  - T cells
OT  - dendritic cells
OT  - granuloma annulare
OT  - infliximab
OT  - macrophages
EDAT- 2019/07/11 06:00
MHDA- 2019/11/14 06:00
CRDT- 2019/07/11 06:00
PHST- 2018/12/21 00:00 [received]
PHST- 2019/05/21 00:00 [accepted]
PHST- 2019/07/11 06:00 [pubmed]
PHST- 2019/11/14 06:00 [medline]
PHST- 2019/07/11 06:00 [entrez]
AID - 10.1111/1346-8138.14981 [doi]
PST - ppublish
SO  - J Dermatol. 2019 Sep;46(9):808-811. doi: 10.1111/1346-8138.14981. Epub 2019 Jul 
      10.